Most Recent
A judge has struck out an allegation by the builder of Sydney’s Opal Tower that insurer Liberty Mutual breached its duty of good faith and has warned Icon to carefully consider whether to re-plead the claim.
The Australian Competition and Consumer Commission has approved France-based Louis Dreyfus' proposed acquisition of ASX-traded cotton gin operator Namoi Cotton, after accepting an undertaking that allayed its competition concerns.
In a first for a Big Four firm, PwC has made good on its promise to appoint an independent chair to its board and has tasked law firm Webb Henderson and former top judge with tracking its progress on other commitments made in the wake of its tax leaks scandal.
A law firm partner has avoided personal liability for costs after expert reports were filed late in a dispute with developer Mirvac over alleged defects in a Sydney apartment complex, having walked back an appeal to “competing commitments” that didn’t wash in court.
After leading the first in a series of class actions by thousands of junior doctors to victory at trial, the applicant in a landmark wage case against Peninsula Health has told a judge the penalty against the Victorian hospital operator must send a clear message.
Mining company Fortescue, which alleges green iron startup Element Zero misused confidential information, is fighting a bid to cross-examine its external lawyer as part of an application to quash search orders.
Johnson Winter Slattery has appointed a technology and communications specialist, bolstering the ranks of its team in Sydney.
Regional air carrier Rex Airlines has filed for voluntary administration after failing to compete with Qantas and Virgin on major routes.
The Queensland Court of Appeal has knocked back a challenge by jailed investment guru Dr Roger Munro to his conviction on three counts of fraud, which landed him a four-and-a-half month prison sentence.
Plaintiff firm Maurice Blackburn will foot the bill for the unsuccessful class action against Monsanto over weed killer Roundup, but the company's reluctance to split the trial in two has come back to bite it.